Lawren VandeVrede
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lawren VandeVrede has a total of 430 co-authors. Here are the top co-authors by number of shared publications:
Adam L. Boxer
Weill Institute for Neurosciences, Department of Neurology, Memory and Aging Center, University of California, 675 Nelson Rising Lane, Suite 190, San Francisco, CA 94143, USA
16 shared publicationsJulio C. Rojas
University of California, San Francisco, San Francisco, CA USA
15 shared publicationsPeter A. Ljubenkov
Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA USA
13 shared publications- Adam M. Staffaroni
Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, USA
9 shared publications - Adam. L. Boxer
Department of Neurology, Weill Institute for Neurosciences, Edward and Pearl Fein Memory and Aging Center, University of California San Francisco, San Francisco, CA
9 shared publications Argentina Lario Lago
Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco
8 shared publications
Latest Publications
- 22 October 2026
- Published by Wolters Kluwer Health in Cognitive and Behavioral Neurology
Quick Conclusions From Slowed Saccades: When Progressive Supranuclear Palsy Overshadows Lewy Body Disease
Antemortem prediction of dementia-causing neurodegenerative disease is challenging, in part due to the frequency of co-occurring diseases. Etiologic diagnosis may be aided by the identification of highly specific clinical features or available biomarkers. Here we present an educational case of an individual with a primary neuropathological diagnosis of lewy body disease (LBD) and contributing progressive supranuclear palsy (PSP). He was clinically diagnosed only with PSP-Richardson syndrome based on ocular motor findings. LBD was not considered despite several inconsistent clinical features. Neuropathological examination showed well-developed transitional/limbic LBD and a very mild burden of PSP. Diagnostic criteria for PSP were just met based on semiquantitative ratings and affected neuroanatomy. No amyloid plaques of Alzheimer disease (AD) were identified, but AD-tau tangles reached Braak stage 4. Postmortem analysis of cerebrospinal fluid showed alpha-synuclein seeding amplification, but no clear evidence for AD. However, plasma biomarkers P-tau181 and P-tau217 suggested AD neuropathological change. Biomarkers may assist in the assessment of multiple etiologies, but they are imperfect and require expert interpretation within clinical contexts. Accurate etiologic prediction requires an understanding of common co-occurring neurodegenerative diseases, cautious interpretation of biomarkers, and knowledge of clinicopathological relationships.
- 22 October 2026
- Published by Wolters Kluwer Health in Cognitive and Behavioral Neurology
Quick Conclusions From Slowed Saccades: When Progressive Supranuclear Palsy Overshadows Lewy Body Disease
Antemortem prediction of dementia-causing neurodegenerative disease is challenging, in part due to the frequency of co-occurring diseases. Etiologic diagnosis may be aided by the identification of highly specific clinical features or available biomarkers. Here we present an educational case of an individual with a primary neuropathological diagnosis of lewy body disease (LBD) and contributing progressive supranuclear palsy (PSP). He was clinically diagnosed only with PSP-Richardson syndrome based on ocular motor findings. LBD was not considered despite several inconsistent clinical features. Neuropathological examination showed well-developed transitional/limbic LBD and a very mild burden of PSP. Diagnostic criteria for PSP were just met based on semiquantitative ratings and affected neuroanatomy. No amyloid plaques of Alzheimer disease (AD) were identified, but AD-tau tangles reached Braak stage 4. Postmortem analysis of cerebrospinal fluid showed alpha-synuclein seeding amplification, but no clear evidence for AD. However, plasma biomarkers P-tau181 and P-tau217 suggested AD neuropathological change. Biomarkers may assist in the assessment of multiple etiologies, but they are imperfect and require expert interpretation within clinical contexts. Accurate etiologic prediction requires an understanding of common co-occurring neurodegenerative diseases, cautious interpretation of biomarkers, and knowledge of clinicopathological relationships.
- Open Access
When Is Amyloid Really Cleared? Substantial Discordance Between Centiloid Quantitation and Visual Reads of Amyloid PET after Amyloid-Targeting Therapy
Amyloid-targeting therapies (ATTs) substantially reduce amyloid PET signal and slow clinical decline in early symptomatic Alzheimer disease. As ATTs enter clinical practice, PET may assess target engagement and guide treatment management, but there is no consensus on how to measure treatment-related amyloid clearance (TRAC). We compared Centiloid quantitation across pipelines and visual reads for interpreting pre– and post-ATT amyloid PET. Methods : We analyzed 18F-florbetapir or 18F-florbetaben PET from 101 patients treated with lecanemab or donanemab: 88 pre-ATT and 54 post-ATT scans, including 41 paired scans. Centiloids were derived using FDA-cleared MIMneuro and two research pipelines (rPOP, CapAIBL) and compared using intraclass correlation coefficients (ICC). Clearance rates were estimated using linear mixed-effects models. Full TRAC was defined on post-ATT scans quantitatively (Results : Treated patients were 74±7 years old; 57% were female, 59% were apolipoprotein E ε4 carriers, and 78% had mild cognitive impairment (22% mild dementia). Centiloid agreement between pipelines was equally high pre– and post-ATT (both ICCs=0.90). Among paired scans (mean treatment duration, 16.7±4.6 months), clearance estimates were similar across pipelines and greater with donanemab (n=15 patients; between –62 and –60 Centiloids/year depending on the pipeline) than lecanemab (n=26; –38 to –36 Centiloids/year; all PConclusion : Centiloid quantitation was robust across pipelines before and after ATT initiation, yielding clearance rates consistent with clinical trials. However, quantitative and visual assessments were markedly discordant after ATT, with an unusually high proportion of scans <11 Centiloids remaining visually positive, warranting cautious interpretation of post-ATT Centiloid values. Larger studies should assess the clinical relevance of these findings and further develop robust approaches to establish full TRAC.
Open AccessWhen Is Amyloid Really Cleared? Substantial Discordance Between Centiloid Quantitation and Visual Reads of Amyloid PET after Amyloid-Targeting Therapy
Amyloid-targeting therapies (ATTs) substantially reduce amyloid PET signal and slow clinical decline in early symptomatic Alzheimer disease. As ATTs enter clinical practice, PET may assess target engagement and guide treatment management, but there is no consensus on how to measure treatment-related amyloid clearance (TRAC). We compared Centiloid quantitation across pipelines and visual reads for interpreting pre– and post-ATT amyloid PET. Methods : We analyzed 18F-florbetapir or 18F-florbetaben PET from 101 patients treated with lecanemab or donanemab: 88 pre-ATT and 54 post-ATT scans, including 41 paired scans. Centiloids were derived using FDA-cleared MIMneuro and two research pipelines (rPOP, CapAIBL) and compared using intraclass correlation coefficients (ICC). Clearance rates were estimated using linear mixed-effects models. Full TRAC was defined on post-ATT scans quantitatively (Results : Treated patients were 74±7 years old; 57% were female, 59% were apolipoprotein E ε4 carriers, and 78% had mild cognitive impairment (22% mild dementia). Centiloid agreement between pipelines was equally high pre– and post-ATT (both ICCs=0.90). Among paired scans (mean treatment duration, 16.7±4.6 months), clearance estimates were similar across pipelines and greater with donanemab (n=15 patients; between –62 and –60 Centiloids/year depending on the pipeline) than lecanemab (n=26; –38 to –36 Centiloids/year; all PConclusion : Centiloid quantitation was robust across pipelines before and after ATT initiation, yielding clearance rates consistent with clinical trials. However, quantitative and visual assessments were markedly discordant after ATT, with an unusually high proportion of scans <11 Centiloids remaining visually positive, warranting cautious interpretation of post-ATT Centiloid values. Larger studies should assess the clinical relevance of these findings and further develop robust approaches to establish full TRAC.
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (3) , e000114
Gene-Environment Interaction in Nonfamilial Corticobasal Syndrome in Monozygotic Twins With Differential Occupational Exposure
Background and ObjectivesCorticobasal syndrome (CBS) is a progressive neurodegenerative disorder often linked to 4-repeat tauopathies. Most CBS cases are nonfamilial and lack identified pathogenic ...
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (3) , e000114
Open AccessGene-Environment Interaction in Nonfamilial Corticobasal Syndrome in Monozygotic Twins With Differential Occupational Exposure
Background and ObjectivesCorticobasal syndrome (CBS) is a progressive neurodegenerative disorder often linked to 4-repeat tauopathies. Most CBS cases are nonfamilial and lack identified pathogenic ...
- Top Cited Papers
- 10 March 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (5) , e214576
Association of [ 18 F]Flortaucipir–PET and Plasma p-Tau217 With Tau Neuropathology in Alzheimer Disease and Other Neurodegenerative Disorders
Evaluating tau biomarkers in patients with autopsy data is critical for validating their sensitivity and specificity to Alzheimer disease (AD) neuropathologic changes (ADNCs). We examined associations between [18F]flortaucipir tau PET, plasma phosphorylated-tau 217 (p-tau217), and AD neuropathology in a cohort of clinically impaired participants from a tertiary dementia center. This was a retrospective study conducted at the University of California San Francisco Neurodegenerative Disease Brain Bank that included all participants with a clinical diagnosis of neurodegenerative disease who underwent antemortem flortaucipir-PET and autopsy from 2013 to 2024. Flortaucipir-PET was acquired 80-100 minutes after injection and normalized to the inferior cerebellar cortex; standardized uptake value ratios (SUVRs) were extracted from the entorhinal cortex (early tau region) and the temporal meta-regions of interest (ROIs) (AD-signature region). Plasma p-tau217 was quantified using Simoa (Janssen) in 56 participants (median [interquartile range, IQR] PET-to-plasma duration: 1.6 months [0.24-3.7]). Semiquantitative rating of AD neurofibrillary tangle (NFT) burden in cortical areas was available for 56 participants. The diagnostic performance of tau PET and plasma p-tau217 was assessed using receiver operating characteristic analysis with cross-validation. We analyzed 73 participants (median [IQR] age: 67 [59-73] years, 60% male, median [IQR] PET-to-autopsy duration: 3.9 [2.1-5.1] years) with primary neuropathologic diagnosis of AD (n = 39), frontotemporal lobar degeneration (tauopathies, n = 26; nontauopathies, n = 4), chronic traumatic encephalopathy (n = 2), and Lewy body disease (n = 2). Flortaucipir SUVRs were elevated in participants with a neuropathologic diagnosis of AD compared with non-AD participants. Consistently elevated PET signal was detected in both the entorhinal cortex and temporal meta-ROIs at NFT Braak stage VI and high ADNC levels. No PET signal elevation was observed at intermediate ADNC levels. AD NFT burden correlated with local flortaucipir SUVRs and plasma p-tau217 concentrations across cortical brain regions. Plasma p-tau217 concentrations increased at Braak stages V and VI and correlated with flortaucipir SUVRs (r's ≥ 0.75). Both markers identified Braak stage V-VI levels with similarly high performance (entorhinal SUVR, area under the curve [AUC] = 0.92 [95% CI 0.91-0.93]; temporal meta-ROI SUVR, AUC = 0.91 [95% CI 0.90-0.92]; plasma p-tau217, AUC = 0.90 [95% CI 0.89-0.91]), but PET outperformed plasma p-tau217 in identifying high/intermediate ADNCs (entorhinal ROI, AUC = 0.94 [95% CI 0.94-0.95]; temporal meta-ROI AUC = 0.94 [95% CI 0.94-0.95]; plasma p-tau217, AUC = 0.89 [95% CI 0.88-0.90]). Flortaucipir-PET and plasma p-tau217 both displayed strong specificity for primary AD neuropathologic diagnosis but limited sensitivity for early tau co-pathology in non-AD diagnoses.
- 10 March 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (5) , e214576
Top Cited PapersAssociation of [ 18 F]Flortaucipir–PET and Plasma p-Tau217 With Tau Neuropathology in Alzheimer Disease and Other Neurodegenerative Disorders
Evaluating tau biomarkers in patients with autopsy data is critical for validating their sensitivity and specificity to Alzheimer disease (AD) neuropathologic changes (ADNCs). We examined associations between [18F]flortaucipir tau PET, plasma phosphorylated-tau 217 (p-tau217), and AD neuropathology in a cohort of clinically impaired participants from a tertiary dementia center. This was a retrospective study conducted at the University of California San Francisco Neurodegenerative Disease Brain Bank that included all participants with a clinical diagnosis of neurodegenerative disease who underwent antemortem flortaucipir-PET and autopsy from 2013 to 2024. Flortaucipir-PET was acquired 80-100 minutes after injection and normalized to the inferior cerebellar cortex; standardized uptake value ratios (SUVRs) were extracted from the entorhinal cortex (early tau region) and the temporal meta-regions of interest (ROIs) (AD-signature region). Plasma p-tau217 was quantified using Simoa (Janssen) in 56 participants (median [interquartile range, IQR] PET-to-plasma duration: 1.6 months [0.24-3.7]). Semiquantitative rating of AD neurofibrillary tangle (NFT) burden in cortical areas was available for 56 participants. The diagnostic performance of tau PET and plasma p-tau217 was assessed using receiver operating characteristic analysis with cross-validation. We analyzed 73 participants (median [IQR] age: 67 [59-73] years, 60% male, median [IQR] PET-to-autopsy duration: 3.9 [2.1-5.1] years) with primary neuropathologic diagnosis of AD (n = 39), frontotemporal lobar degeneration (tauopathies, n = 26; nontauopathies, n = 4), chronic traumatic encephalopathy (n = 2), and Lewy body disease (n = 2). Flortaucipir SUVRs were elevated in participants with a neuropathologic diagnosis of AD compared with non-AD participants. Consistently elevated PET signal was detected in both the entorhinal cortex and temporal meta-ROIs at NFT Braak stage VI and high ADNC levels. No PET signal elevation was observed at intermediate ADNC levels. AD NFT burden correlated with local flortaucipir SUVRs and plasma p-tau217 concentrations across cortical brain regions. Plasma p-tau217 concentrations increased at Braak stages V and VI and correlated with flortaucipir SUVRs (r's ≥ 0.75). Both markers identified Braak stage V-VI levels with similarly high performance (entorhinal SUVR, area under the curve [AUC] = 0.92 [95% CI 0.91-0.93]; temporal meta-ROI SUVR, AUC = 0.91 [95% CI 0.90-0.92]; plasma p-tau217, AUC = 0.90 [95% CI 0.89-0.91]), but PET outperformed plasma p-tau217 in identifying high/intermediate ADNCs (entorhinal ROI, AUC = 0.94 [95% CI 0.94-0.95]; temporal meta-ROI AUC = 0.94 [95% CI 0.94-0.95]; plasma p-tau217, AUC = 0.89 [95% CI 0.88-0.90]). Flortaucipir-PET and plasma p-tau217 both displayed strong specificity for primary AD neuropathologic diagnosis but limited sensitivity for early tau co-pathology in non-AD diagnoses.
- 1 March 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (1)
Continuous At-Home Monitoring of Nighttime Bed Behavior in Frontotemporal Dementia
Sleep and circadian disturbances are common yet understudied in frontotemporal dementia (FTD). Advances in non-invasive digital monitoring technology enable capture of real-time objective nighttime behaviors in naturalistic settings. We examined feasibility and utility of an unobtrusive, under-the-mattress sensor to monitor long-term bed behaviors in a sample of adults with FTD and their study partners. This longitudinal observational study continuously monitored bed behaviors in participants with FTD recruited from the ALLFTD study for up to two years using an Emfit™ Movement Monitor. Metrics were derived from each session in bed: duration in bed, time of bed-entry/exit, number of tosses/turns, and number of bed-exits. Bivariate relationships between baseline bed behaviors (aggregated across the first 30 days) and clinical characteristics (FTD vs. control; clinical dementia rating) were tested. Linear mixed-effects regressions examined longitudinal associations between baseline clinical severity and bed behaviors over time. To examine differential seasonal shifts in nightly bed behaviors, Fourier basis functions modeled nightly duration in bed over a full calendar year separately by clinical severity groups (controls vs. mild FTD vs. moderate-to-severe FTD). Participants were 16 adults with FTD (mean age = 67; 69% male) and 12 study partner comparators (mean age = 62; 33% male). At baseline, participants with FTD had higher average durations in bed (mean difference=1.8, 95%CI [0.03, 3.61], p=0.046), more variability in durations in bed across days (mean difference=1.8, 95%CI [0.14, 3.37], p=0.035), and more bed exits than study partners (log-transformed; mean difference=0.5, 95%CI [0.02, 1.06], p=0.042). Longitudinally, person-specific linear trajectories of bed behaviors revealed that higher baseline clinical severity associated with significantly steeper increases in tosses/turns over time (β=0.15, 95%CI [0.05, 0.25], p=0.009). Those with more severe FTD also had an attenuated sleep-behavioral response to seasonal daylight shifts (β=0.23, 95%CI [0.13, 0.33], p<0.001). Findings demonstrate the feasibility of long-term, non-invasive nighttime behavior monitoring using bed sensors, highlighting their utility to monitor disease progression in FTD with potential to detect person-specific changes and assess treatment effects. Further research is needed to explore underlying mechanisms of sleep disturbances in FTD and develop targeted interventions to improve sleep and subsequent quality of life for individuals with FTD.
- 1 March 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (1)
Continuous At-Home Monitoring of Nighttime Bed Behavior in Frontotemporal Dementia
Sleep and circadian disturbances are common yet understudied in frontotemporal dementia (FTD). Advances in non-invasive digital monitoring technology enable capture of real-time objective nighttime behaviors in naturalistic settings. We examined feasibility and utility of an unobtrusive, under-the-mattress sensor to monitor long-term bed behaviors in a sample of adults with FTD and their study partners. This longitudinal observational study continuously monitored bed behaviors in participants with FTD recruited from the ALLFTD study for up to two years using an Emfit™ Movement Monitor. Metrics were derived from each session in bed: duration in bed, time of bed-entry/exit, number of tosses/turns, and number of bed-exits. Bivariate relationships between baseline bed behaviors (aggregated across the first 30 days) and clinical characteristics (FTD vs. control; clinical dementia rating) were tested. Linear mixed-effects regressions examined longitudinal associations between baseline clinical severity and bed behaviors over time. To examine differential seasonal shifts in nightly bed behaviors, Fourier basis functions modeled nightly duration in bed over a full calendar year separately by clinical severity groups (controls vs. mild FTD vs. moderate-to-severe FTD). Participants were 16 adults with FTD (mean age = 67; 69% male) and 12 study partner comparators (mean age = 62; 33% male). At baseline, participants with FTD had higher average durations in bed (mean difference=1.8, 95%CI [0.03, 3.61], p=0.046), more variability in durations in bed across days (mean difference=1.8, 95%CI [0.14, 3.37], p=0.035), and more bed exits than study partners (log-transformed; mean difference=0.5, 95%CI [0.02, 1.06], p=0.042). Longitudinally, person-specific linear trajectories of bed behaviors revealed that higher baseline clinical severity associated with significantly steeper increases in tosses/turns over time (β=0.15, 95%CI [0.05, 0.25], p=0.009). Those with more severe FTD also had an attenuated sleep-behavioral response to seasonal daylight shifts (β=0.23, 95%CI [0.13, 0.33], p<0.001). Findings demonstrate the feasibility of long-term, non-invasive nighttime behavior monitoring using bed sensors, highlighting their utility to monitor disease progression in FTD with potential to detect person-specific changes and assess treatment effects. Further research is needed to explore underlying mechanisms of sleep disturbances in FTD and develop targeted interventions to improve sleep and subsequent quality of life for individuals with FTD.
- Open Access
- 24 January 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (3) , 100486
Potential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration
- 24 January 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (3) , 100486
Open AccessPotential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration
- Open Access
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S5) , e099838
Overview of tau biology as it relates to Alzheimer's pathophysiology, symptoms, and therapeutic development
The protein tau is central to the pathophysiology of many neurodegenerative diseases, including Alzheimer’s disease (AD). Tau is ubiquitously expressed throughout the brain, and misfolded, insoluble tau protein deposits have been found at autopsy in neurons and glia in numerous neurodegenerative diseases, called tauopathies. In AD, a secondary tauopathy, aggregation of tau temporally follows amyloid plaque development. In AD, as in other tauopathies, the localization of tau corresponds with the resulting clinical features, and the amount of tau tangles seen on autopsy or positron emission tomography (PET) correlates with symptom severity throughout different stages of disease. As with amyloid, several lines of genetic evidence support tau’s role in neurodegeneration, particularly pathogenic variants in the MAPT gene that codes for tau, which result in a diverse spectrum of clinical presentations, collectively called primary tauopathies. The normal physiologic role of tau is likely manifold, but it is a soluble cytoplasmic protein that interacts with and potentially stabilizes microtubules through a conserved microtubule binding region. However, the proposed role of tau in neurodegenerative disease is thought to be a toxic gain of function, supported by genetic evidence from genome wide association studies (GWAS) that have only identified gain‐of‐function variants. Additional evidence is found in nonclinical animal models, including tau knockout mice that have little to no apparent phenotype. Pathogenic species of tau are likely driven and defined by specific post‐translational modifications, e.g., amyloid‐induced hyperphosphorylation in the case of AD. The specific mechanism of propagation after toxic species of tau are produced is through cell‐to‐cell spread after an initial “seeding” event. In several neurodegenerative diseases, electronic microscopy has revealed distinct tau conformations specific to different tauopathies, each of which may be a unique seed. Targeting this tau toxic gain‐of‐function is possible through numerous pharmacological approaches, and early evidence from clinical trials where tau is pharmacologically reduced has shown reduction to be generally safe and well‐tolerated.
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S5) , e099838
Open AccessOverview of tau biology as it relates to Alzheimer's pathophysiology, symptoms, and therapeutic development
The protein tau is central to the pathophysiology of many neurodegenerative diseases, including Alzheimer’s disease (AD). Tau is ubiquitously expressed throughout the brain, and misfolded, insoluble tau protein deposits have been found at autopsy in neurons and glia in numerous neurodegenerative diseases, called tauopathies. In AD, a secondary tauopathy, aggregation of tau temporally follows amyloid plaque development. In AD, as in other tauopathies, the localization of tau corresponds with the resulting clinical features, and the amount of tau tangles seen on autopsy or positron emission tomography (PET) correlates with symptom severity throughout different stages of disease. As with amyloid, several lines of genetic evidence support tau’s role in neurodegeneration, particularly pathogenic variants in the MAPT gene that codes for tau, which result in a diverse spectrum of clinical presentations, collectively called primary tauopathies. The normal physiologic role of tau is likely manifold, but it is a soluble cytoplasmic protein that interacts with and potentially stabilizes microtubules through a conserved microtubule binding region. However, the proposed role of tau in neurodegenerative disease is thought to be a toxic gain of function, supported by genetic evidence from genome wide association studies (GWAS) that have only identified gain‐of‐function variants. Additional evidence is found in nonclinical animal models, including tau knockout mice that have little to no apparent phenotype. Pathogenic species of tau are likely driven and defined by specific post‐translational modifications, e.g., amyloid‐induced hyperphosphorylation in the case of AD. The specific mechanism of propagation after toxic species of tau are produced is through cell‐to‐cell spread after an initial “seeding” event. In several neurodegenerative diseases, electronic microscopy has revealed distinct tau conformations specific to different tauopathies, each of which may be a unique seed. Targeting this tau toxic gain‐of‐function is possible through numerous pharmacological approaches, and early evidence from clinical trials where tau is pharmacologically reduced has shown reduction to be generally safe and well‐tolerated.
- Open Access
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S7) , e108915
Phase 1b/2a, 6‐month, randomized, double‐blind, placebo‐controlled study of the safety/tolerability and preliminary evidence of efficacy of a tau‐targeted therapeutic in patients with corticobasal syndrome
Background: Corticobasal syndrome (CBS) is a devastating and untreatable neurodegenerative disease that interferes with cognition, movement, and behavior, and only a handful of clinical trials have been conducted in this population. 1 CBS is predominantly caused by tau, but two different types of tau can accumulate: 4R‐tauopathy (CBS‐4RT) or the tau in Alzheimer’s disease (CBS‐AD). 2 Recently, we demonstrated that a tau blood test ( p ‐tau217) can distinguish between CBS‐AD and CBS‐4RT, 3 important because tauopathies may respond differently to therapeutics. 4 This precision diagnosis permits diagnostic refinement of CBS in clinical trials. Methods: The primary objective is the safety/tolerability of 6 months of a tau‐directed therapeutic. The secondary objective is to evaluate target engagement by measuring tau in CSF and plasma. The exploratory objective is evaluation of clinical efficacy using clinical, fluid, and imaging endpoints. A total of N=24 participants with a clinical diagnosis of CBS will be stratified with plasma p ‐tau217 (goal n=12 per arm) and randomized 2:1 to a tau‐directed therapeutics. The study drug will be administered for 6 months, and safety/tolerability, target engagement, and clinical efficacy will be tested in both a primary (CBS‐4RT) and a secondary tauopathy (CBS‐AD). The current study design calls for a single site with an expected launch date in 2025, with an additional 6‐month open‐label extension. Results: This trial design represents the first “within‐syndrome” basket design in CBS using precision diagnosis to stratify by neuropathological etiology using the plasma p ‐tau217 biomarker; the first use of a tau‐directed therapeutic simultaneously in both an AD and non‐AD tauopathy in a single trial; and the first use of several novel fluid biomarkers of tau engagement (e.g. MTBR‐tau275/282). Conclusion: A stratified “basket trial” design is a viable mechanism to enroll clinical sub‐cohorts of corticobasal syndrome to test tau‐directed therapeutics in this population.
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S7) , e108915
Open AccessPhase 1b/2a, 6‐month, randomized, double‐blind, placebo‐controlled study of the safety/tolerability and preliminary evidence of efficacy of a tau‐targeted therapeutic in patients with corticobasal syndrome
Background: Corticobasal syndrome (CBS) is a devastating and untreatable neurodegenerative disease that interferes with cognition, movement, and behavior, and only a handful of clinical trials have been conducted in this population. 1 CBS is predominantly caused by tau, but two different types of tau can accumulate: 4R‐tauopathy (CBS‐4RT) or the tau in Alzheimer’s disease (CBS‐AD). 2 Recently, we demonstrated that a tau blood test ( p ‐tau217) can distinguish between CBS‐AD and CBS‐4RT, 3 important because tauopathies may respond differently to therapeutics. 4 This precision diagnosis permits diagnostic refinement of CBS in clinical trials. Methods: The primary objective is the safety/tolerability of 6 months of a tau‐directed therapeutic. The secondary objective is to evaluate target engagement by measuring tau in CSF and plasma. The exploratory objective is evaluation of clinical efficacy using clinical, fluid, and imaging endpoints. A total of N=24 participants with a clinical diagnosis of CBS will be stratified with plasma p ‐tau217 (goal n=12 per arm) and randomized 2:1 to a tau‐directed therapeutics. The study drug will be administered for 6 months, and safety/tolerability, target engagement, and clinical efficacy will be tested in both a primary (CBS‐4RT) and a secondary tauopathy (CBS‐AD). The current study design calls for a single site with an expected launch date in 2025, with an additional 6‐month open‐label extension. Results: This trial design represents the first “within‐syndrome” basket design in CBS using precision diagnosis to stratify by neuropathological etiology using the plasma p ‐tau217 biomarker; the first use of a tau‐directed therapeutic simultaneously in both an AD and non‐AD tauopathy in a single trial; and the first use of several novel fluid biomarkers of tau engagement (e.g. MTBR‐tau275/282). Conclusion: A stratified “basket trial” design is a viable mechanism to enroll clinical sub‐cohorts of corticobasal syndrome to test tau‐directed therapeutics in this population.
- Open Access
- 13 November 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (11) , e70891
Blood‐based Alzheimer's disease biomarkers in a behavioral neurology clinic: Real‐world implementation, clinical utility, and diagnostic performance
INTRODUCTION: Blood‐based biomarkers (BBMs) for Alzheimer's disease (AD), including plasma phosphorylated tau (p‐tau), are increasingly used in clinical practice, but “real‐world” implementation patterns, context‐of‐use (COU), clinical utility, and diagnostic performance are incompletely understood. METHODS: A retrospective analysis of the first year of BBM use in a tertiary level cognitive neurology subspecialty clinic was conducted, including review of COU, impact on diagnostic certainty, prescription of AD‐related medications, and additional AD‐biomarker testing. RESULTS: P‐tau181 was ordered frequently to detect AD in a diverse cohort, across a wide spectrum of COU, including typical, early‐onset, and atypical AD presentations; mixed etiology; AD co‐pathology; and borderline symptoms. P‐tau181 impacted diagnostic confidence, AD‐related medication prescription, and follow‐on testing. Renal impairment was a common confounder. CONCLUSIONS: Implementation of BBMs was feasible and impactful in a memory clinic, especially in a diagnostically complex and diverse patient population, underscoring the need for additional data from real‐world settings. Highlights: Blood‐based biomarkers (BBMs) were quickly adopted and accelerated precision diagnosis in a large memory clinic. BBM use cases were diverse and included all stages/types of AD and non‐AD syndromes. Plasma p‐tau has the potential to impact diagnostic certainty and clinical decision making. Diagnostic performance of p‐tau is reasonable, though renal function impacts overall accuracy.
- 13 November 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (11) , e70891
Open AccessBlood‐based Alzheimer's disease biomarkers in a behavioral neurology clinic: Real‐world implementation, clinical utility, and diagnostic performance
INTRODUCTION: Blood‐based biomarkers (BBMs) for Alzheimer's disease (AD), including plasma phosphorylated tau (p‐tau), are increasingly used in clinical practice, but “real‐world” implementation patterns, context‐of‐use (COU), clinical utility, and diagnostic performance are incompletely understood. METHODS: A retrospective analysis of the first year of BBM use in a tertiary level cognitive neurology subspecialty clinic was conducted, including review of COU, impact on diagnostic certainty, prescription of AD‐related medications, and additional AD‐biomarker testing. RESULTS: P‐tau181 was ordered frequently to detect AD in a diverse cohort, across a wide spectrum of COU, including typical, early‐onset, and atypical AD presentations; mixed etiology; AD co‐pathology; and borderline symptoms. P‐tau181 impacted diagnostic confidence, AD‐related medication prescription, and follow‐on testing. Renal impairment was a common confounder. CONCLUSIONS: Implementation of BBMs was feasible and impactful in a memory clinic, especially in a diagnostically complex and diverse patient population, underscoring the need for additional data from real‐world settings. Highlights: Blood‐based biomarkers (BBMs) were quickly adopted and accelerated precision diagnosis in a large memory clinic. BBM use cases were diverse and included all stages/types of AD and non‐AD syndromes. Plasma p‐tau has the potential to impact diagnostic certainty and clinical decision making. Diagnostic performance of p‐tau is reasonable, though renal function impacts overall accuracy.
- Open Access
- 1 October 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (10) , 469
Implementation of an Alzheimer’s Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study
Background/Objectives: A high-performing blood biomarker (BBM) test for Alzheimer’s disease (AD) represents an accurate, accessible, and scalable tool to aid healthcare professionals (HCPs) evaluating patients presenting with signs or symptoms of mild cognitive impairment (MCI) or dementia. However, implementation of AD blood tests into clinical practice has not been extensively evaluated. The objective of this study was to assess the implementation of the multi-analyte PrecivityAD2™ blood test (C2N Diagnostics, LLC, St. Louis, MO, USA) into the clinical workflow of memory care clinics. Methods: A total of 8 HCPs (neurologists, geriatricians, geriatric psychiatrists) who served as site directors from 8 outpatient sites that evaluated 203 cognitively symptomatic patients were included in this sub-study of the real-world QUIP II Study (NCT06025877). Implementation of this blood test was assessed through surveying these HCPs using published frameworks including the Technology Acceptance Model, net promoter score, and forced choice preference questions. These assessments were analyzed using Wilcoxon signed-rank test, Fisher’s Exact test, and Wilcoxon signed-rank test, respectively. Results: HCPs reported acceptance scores that averaged 9.6 out of 10 (p < 0.0001, effect size 0.840): the test’s contribution to clinical decision-making as well as the ease of understanding test results received the highest ratings. The net promoter score was 75 (p < 0.0001), exceeding the typical benchmark of 30 reported as good levels of satisfaction in healthcare settings. The APS2 results and individual blood analyte results were rated with similar preference around their roles in HCP clinical decision-making. Conclusions: The results indicate early evidence of user acceptance and recognition by HCPs that this AD blood test can personalize the clinical care pathway for evaluating cognitively symptomatic patients.
- 1 October 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (10) , 469
Open AccessImplementation of an Alzheimer’s Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study
Background/Objectives: A high-performing blood biomarker (BBM) test for Alzheimer’s disease (AD) represents an accurate, accessible, and scalable tool to aid healthcare professionals (HCPs) evaluating patients presenting with signs or symptoms of mild cognitive impairment (MCI) or dementia. However, implementation of AD blood tests into clinical practice has not been extensively evaluated. The objective of this study was to assess the implementation of the multi-analyte PrecivityAD2™ blood test (C2N Diagnostics, LLC, St. Louis, MO, USA) into the clinical workflow of memory care clinics. Methods: A total of 8 HCPs (neurologists, geriatricians, geriatric psychiatrists) who served as site directors from 8 outpatient sites that evaluated 203 cognitively symptomatic patients were included in this sub-study of the real-world QUIP II Study (NCT06025877). Implementation of this blood test was assessed through surveying these HCPs using published frameworks including the Technology Acceptance Model, net promoter score, and forced choice preference questions. These assessments were analyzed using Wilcoxon signed-rank test, Fisher’s Exact test, and Wilcoxon signed-rank test, respectively. Results: HCPs reported acceptance scores that averaged 9.6 out of 10 (p < 0.0001, effect size 0.840): the test’s contribution to clinical decision-making as well as the ease of understanding test results received the highest ratings. The net promoter score was 75 (p < 0.0001), exceeding the typical benchmark of 30 reported as good levels of satisfaction in healthcare settings. The APS2 results and individual blood analyte results were rated with similar preference around their roles in HCP clinical decision-making. Conclusions: The results indicate early evidence of user acceptance and recognition by HCPs that this AD blood test can personalize the clinical care pathway for evaluating cognitively symptomatic patients.